Request Demo

Last update 26 Jul 2025

Avacincaptad pegol

Last update 26 Jul 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

RNA aptamer

Synonyms

Anti-C5 aptamer, Avacincaptad pegol sodium (USAN), Zimura

+ [5]

Target

Action

inhibitors

Mechanism

C5 inhibitors(Complement C5 inhibitors)

Therapeutic Areas

Congenital DisordersEye DiseasesNervous System Diseases+ [1]

Active Indication

Geographic AtrophyAge Related Macular DegenerationBlindness+ [3]

Inactive Indication

Idiopathic Polypoidal Choroidal VasculopathyWet age-related macular degeneration

Originator Organization

Ocular Therapeutix, Inc.

Active Organization

IVERIC bio, Inc.Astellas Pharma Global Development, Inc.

Archemix Corp.

+ [3]

Inactive Organization

Ophthotech Corp. (New Jersey)

License Organization

DelSiTech Oy

Astellas Pharma, Inc.

Archemix Corp.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (04 Aug 2023),

Geographic Atrophy

RegulationPriority Review (United States), Breakthrough Therapy (United States)

Structure/Sequence

Boost your research with our RNA technology data.

view full example data

Sequence Code 29451050

Source: *****

Clinical Trials associated with Avacincaptad pegol

NCT06961370

/ RecruitingPhase 1

A Phase I, Multi-center, Multi-part Study to Investigate Safety, Tolerability, PK, PD, and Immunogenicity of RO7669330 Intravitreal Injections in Participants With GA Secondary to AMD: Part 1A: Open-label, MAD; Part 1B: Randomized PD Pilot; Part 2: Masked, Randomized, Active-comparator-controlled

The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in GA secondary to AMD after multiple unilateral intravitreal (IVT) doses.

Start Date16 Jul 2025

Sponsor / Collaborator

Roche Holding AG

NCT06970665

/ RecruitingPhase 3

A Phase 3/4, Multicenter, Single-arm Clinical Study to Assess the Safety of Intravitreal Administration of ASP3021 in Participants in Japan With Geographic Atrophy Secondary to Age-related Macular Degeneration

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their vision over time. AMD damages the macula, which is in the middle of the retina - the light sensitive part at the back of the eye. In AMD, the cells in the macula die over time, usually over several years, leading to vision loss. When AMD gets worse, it can turn into either geographic atrophy (GA), neovascular AMD, or both.
This study is for people in Japan of 40 years of age or older, who have geographic atrophy.
The main aim of this study is to collect information about the safety of ASP3021 and how well people tolerate treatment with ASP3021.
During the study, people will receive monthly injections of ASP3021 for 12 months. ASP3021 is given by injection into the affected eye. This procedure is called an intravitreal injection.
People will be in the study for about 1 year. People will visit their study clinic several times for health checks.

Start Date08 Jul 2025

Sponsor / Collaborator

Astellas Pharma, Inc.

NCT06779773

/ RecruitingNot Applicable

A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY?) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision.
Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy.
This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor has decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas).
People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for up to 3 years or up to 5 years, depending on when they start the study.

Start Date22 Jan 2025

Sponsor / Collaborator

Astellas Pharma Global Development, Inc.

100 Clinical Results associated with Avacincaptad pegol

100 Translational Medicine associated with Avacincaptad pegol

100 Patents (Medical) associated with Avacincaptad pegol

Literatures (Medical) associated with Avacincaptad pegol

01 Aug 2025·AMERICAN JOURNAL OF OPHTHALMOLOGY

Ocular Adverse Events Associated with Pegcetacoplan and Avacincaptad Pegol for Geographic Atrophy: A Population-Based Pharmacovigilance Study

Article

Author: Kertes, Peter J ; Muni, Rajeev H ; Popovic, Marko M ; Mihalache, Andrew ; Kailani, Zeena

OBJECTIVE:

To evaluate the postmarketing ocular adverse events (AEs) reported for avacincaptad pegol and pegcetacoplan, the only Food and Drug Administration (FDA)-approved treatments for geographic atrophy (GA).

DESIGN:

Retrospective pharmacovigilance analysis.

SUBJECTS:

Ocular AE reports in the FDA Adverse Event Reporting System (FAERS) in which pegcetacoplan or avacincaptad pegol was identified as the primary suspect drug were analyzed.

METHODS:

Using the OpenVigil 2.1 data mining software, we conducted a retrospective pharmacovigilance analysis of the FAERS database from inception to December 2024. We conducted disproportionality analyses to assess reporting odds ratios (RORs) for specific drug-AE combinations compared with all other drugs in the database.

MAIN OUTCOME MEASURES:

Ocular AEs were evaluated.

RESULTS:

A total of 752 and 80 patients with AEs secondary to pegcetacoplan and avacincaptad pegol, respectively, were identified. Ocular AEs disproportionately overreported for pegcetacoplan included anterior segment (iris) hemorrhage (ROR 1767, 95% CI 538-5803), iris neovascularization (ROR 1248, 95% CI 502-3099), choroidal neovascularization (ROR 1328, 95% CI 956-1845), intraocular injection complication (ROR 2552, 95% CI 1607-4053), hemorrhagic occlusive retinal vasculitis (ROR 4606, 95% CI 2000-10,611), retinal occlusive vasculitis (ROR 2352, 95% CI 1313-4212), and bacterial endophthalmitis (ROR 1260, 95% CI 613-2589). Ocular AEs disproportionately overreported for avacincaptad pegol included choroidal neovascularization (ROR 1169, 95% CI 426-3205), vitritis (ROR 782, 95% CI 316-1936), dry age-related macular degeneration (ROR 684, 95% CI 316-1936), and cystoid macular edema (ROR 445, 95% CI 140-1412).

CONCLUSIONS:

Current prescribing patterns indicate that a broader spectrum of ocular AEs were reported for pegcetacoplan than avacincaptad pegol. These findings aim to enhance clinicians' understanding of the safety profiles of these agents, enabling informed patient care and heightened vigilance of these novel GA treatments.

01 Jun 2025·Ophthalmology and Therapy

Clinical Outcomes of Treatment of Geographic Atrophy: A Narrative Review

Review

Author: Torp, Thomas Lee ; Vergmann, Anna Stage ; Nissen, Anne Helene Køllund

RATIONALE:

In 2023, the U.S. Food and Drug Administration approved pegcetacoplan (SYFOVRE) as the first therapeutic option for geographic atrophy (GA), a previously untreatable condition associated with age-related macular degeneration. Following this, avacincaptad pegol (Izervay) was also approved for GA treatment, further expanding therapeutic options.

OBJECTIVES:

This article aims to give an overview of the clinical outcomes of GA treatment and to discuss which patient groups may benefit most from these therapies.

METHODS:

A review of the literature was conducted using the databases PubMed, Cochrane Library, and ClinicalTrials.gov. The search yielded six relevant studies.

CONCLUSIONS:

The management of geographic atrophy has advanced with therapies like pegcetacoplan and avacincaptad pegol showing clear benefits in slowing lesion growth. However, safety concerns, such as neovascular complications, persist. Photobiomodulation and dietary supplementation provide alternative options with modest benefits, particularly in the early stages. Larger studies are needed to confirm long-term safety, efficacy, and optimal treatment strategies.

06 May 2025·RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Silicone oil microdroplets from syringes with intravitreal anti-vascular endothelial growth factor and complement inhibitor injections

Article

Author: Wei, Libby ; Thompson, John T. ; Fan, Xiaoxuan ; Lee, Erica

Purpose::

To quantify the amount of silicone oil in intravitreal anti-vascular endothelial growth factor and complement inhibitor injections in prefilled and commercial syringes (silicone-lubricated and silicone-free).

Methods::

Patients deemed clinically appropriate to receive one of five intravitreal medications received the recommended dose. Syringes were overfilled such that 0.01-0.04mL remained after injection for analysis. Aflibercept and ranibizumab were available in prefilled syringes. Pegcetacoplan, faricimab, and avacincaptad pegol were prepared with Becton Dickinson polycarbonate (BD) syringes. Faricimab was also prepared in Ocuject VitreJect® (OV) silicone-free syringes. Samples were analyzed using spectral flow cytometry.

Results::

Silicone oil was found in all syringes. The lowest amounts of silicone oil were found in the Mili-Q water in OV syringes (4.02±0.3 particles per microliter) and ranibizumab 0.5 mg prefilled syringes (8.33±3.1). Intermediate levels of silicone oil were detected in aflibercept prefilled syringes (35.5±21.8) and faricimab in OV syringes (74.6±10.1), significantly greater than Mili-Q water in OV syringes and ranibizumab. Significantly higher levels of silicone oil were found with faricimab (324.9±30), pegcetacoplan (378.1±379.6), and avacincaptad pegol (113.5±14) in BD syringes than the low or intermediate groups. The filter needles used to draw up medications from vials likely contributed to the amount of silicone oil detected in the samples.

Conclusions::

Commonly used BD polycarbonate syringes for intravitreal injections caused significantly higher levels of silicone oil to be injected into the eye than prefilled or silicone free syringes. Repeated injections with more viscous intravitreal drugs increase the amount of silicone oil in the vitreous, leading to symptomatic floaters.

142

News (Medical) associated with Avacincaptad pegol

18 Jul 2025

·www.fiercepharma.com

Fierce Pharma Asia—China biotech deal boom; Takeda's narcolepsy win; Sino Biopharm's LaNova buyout

Rising biotech deals involving Chinese drugs, Takeda's positive OX2R readouts, and LaNova's acquisition by Sino Biopharm made our news this week. Biotech deals involving assets developed in China are surging, a Jefferies report shows. Takeda is preparing its narcolepsy candidate oveporexton for an FDA filing after two positive phase 3 readouts. Merck & Co.'s PD-1xVEGF partner is being acquired. And more.1. China biotechs ‘reshaping’ US biopharma as outlicensing deals rise 11%: Jefferies reportAbout a third of biopharma’s outlicensing deal value in the first quarter of 2025 centered on Chinese assets, versus 21% during the same period in both 2024 and 2023, according to Jefferies. Since 2022, China biotechs have developed 639 first-in-class drug candidates, a sharp rise compared with prior years, Jefferies tallied.2. Takeda’s narcolepsy blockbuster hopeful secures double phase 3 wins, teeing up FDA filingTakeda’s OX2R agonist oveporexton has hit the mark in two phase 3 narcolepsy trials. The FirstLight and RadiantLight trials met their primary endpoints showing statistically significant improvements for the drug compared with placebo in excessive daytime sleepiness, as measured by the Maintenance of Wakefulness Test at week 12. The company is now preparing for an FDA approval filing.3. Sino Biopharm buys Merck's PD-1xVEGF bispecific partner LaNova for up to $951MLaNova Medicines, from which Merck & Co. recently licensed a PD-1xVEGF bispecific candidate, is being bought out by Chinese compatriot Sino Biopharmaceutical in a deal worth up to $951 million. In addition, LaNova also provided AstraZeneca with a GPRC5D-targeting antibody-drug conjugate. Before the LaNova transaction, very few, if any, Chinese pharmas have acquired innovative domestic biotechs.4. For Lundbeck and Otsuka's PTSD filing, FDA questions Rexulti efficacy after failed phase 3For an upcoming advisory committee meeting, the FDA flagged “discordant results” from two phase 3 trials that Lundbeck and Otsuka are using in their application for Rexulti, in combination with Viatris’ Zoloft, as a treatment for post-traumatic stress disorder. The FDA is asking experts to weigh in on whether an exploratory phase 2 study can overcome one negative phase 3.5. Otsuka inks $613M deal for Swedish biotech's autoimmune antibodiesOtsuka is paying $33 million upfront for Cantargia’s IL1RAP antibody, CAN10, as well as a backup candidate, against autoimmune and inflammatory disorders. The deal also includes up to $580 million in milestone payments and gives the Japanese drugmaker exclusive first rights of negotiation for Cantargia’s next-gen IL1RAP programs.6. Sun Pharma's alopecia med Leqselvi hits US market after Incyte patent settlementSun Pharma has reached a patent settlement with Incyte so the Indian company can launch its JAK inhibitor Leqselvi in the U.S. for severe alopecia areata. Sun will pay an undisclosed upfront payment plus royalty payments until the related patents expire. The deal ended a lawsuit in which Incyte claimed that Leqselvi would infringe on patents around its blockbuster ruxolitinib.7. FDA hands down citations to 3 drugmakers after inspections found contamination, testing concernsMeanwhile, a Sun Pharma plan in Gujarat, India was subject to a 19-page, eight-observation Form 483 following an FDA inspection in June. Some citations, such as “poor aseptic behavior and inadequate environmental monitoring,” had previously been flagged in an FDA warning letter in 2022. Separately, a Daewoo Pharm site in Busan, Korea, and a Glenmark facility in Madhya Pradesh, India, received FDA warning letters.Other News of Note:8. Astellas reports 22% sales bump for Izervay, expects trend to continue this year9. China sentences Astellas exec to 3.5 years in prison for espionage (Bloomberg)10. Hengrui's GLP-1/GIP agonist reports 18% weight loss in phase 3 trial, readies China push11. Acumen taps JCR’s blood-brain barrier tech for $555M Alzheimer’s deal12. GSK expands Medicines Patent Pool deal to allow generic production of cabotegravir for HIV treatment13. Kowa licenses Nicox’s intraocular pressure eye drop for up to €191.5M (release)14. Korea’s Illimis raises $42M series B to advance Alzheimer’s candidate (release)

Phase 3Acquisition

10 Jul 2025

·www.fiercepharma.com

Astellas reports 22% sales bump for Izervay, expects trend to continue this year

Astellas reported a 22% sequential increase in quarterly sales of geographic atrophy drug Izervay and is projecting booming sales increases for the rest of the year and beyond. After reporting a 15% sequential decline in Izervay sales for the opening quarter of this year, Astellas has reversed the momentum for its geographic atrophy (GA) treatment and is projecting the upward trend to continue this year.In an investor event on Wednesday—three weeks ahead of its quarterly report—Astellas revealed a 22% sequential increase in Izervay sales for the period ending on June 30. The injected C5 inhibitor generated revenue of 15.9 billion Japanese yen ($110 million) in the most recent quarter, up from 13.8 billion Japanese yen ($91 million) in the first quarter.Astellas sees Izervay’s growth continuing to track upward—in the “high 20s or above"—for the next three quarters and is reiterating its fiscal year sales guidance of 105 billion Japanese yen ($750 million).In the longer term, Astellas is now tabbing peak sales for Izervay to reach between 200 billion and 400 billion Japanese yen ($1.3 billion to $2.6 billion) in the U.S. alone. Those figures match the company’s previous projection for peak global sales.Some analysts, however, aren’t buying into Astellas’ rosy expectations just yet. Despite the increase in quarterly sales, the figures came up far short of consensus, which were based largely on the company’s annual sales projection, according to analysts from ISI Evercore.“We wouldn’t be surprised to see Astellas miss their aggressive FY25 guidance,” they wrote in a note to investors.Meanwhile, analysts at Mizuho Securities have doubts about the growth of the GA market as portrayed by the company. Astellas said on Wednesday that, by 2029, it expects to treat at least 35% of the GA patient population in the U.S., crediting “broader upstream awareness and more patient referrals to retina specialists.”“Our biggest concern lies with an overall GA market where growth is potentially stalling,” Mizuho analyst Graig Suvannavejh, Ph.D., wrote in a note to investors, citing recent discussions with key opinion leaders (KOLs). “Despite Astellas' vision of future growth for Izervay in 2025 and beyond, we question what it will take for the CI class to meaningfully grow over time.” It's uncertain what this all means for Astellas’ rival in the GA market, Apellis. Two months ago, the Massachusetts company revealed sales of $130 million in the first quarter for Syfovre, which were down 22% sequentially.The company’s CEO, Cedric Francois, M.D., Ph.D., blamed inventory fluctuations and funding shortfalls in copay assistance programs for the sales decline.Eyes will be on Apellis when it reports its second quarter sales to see if Syfovre gets a similar sequential bump, which would be “supportive of a growing market,” Mizuho wrote.“On the other hand, given KOL feedback we've been hearing of a relatively slow-growing/flat market, there's potential of Izervay gaining at Syfovre's expense,” the analysts added. Astellas has had its own set of problems hindering the launch of Izervay. Early this year, the company took an impairment charge of 115 billion Japanese yen ($760 million) because of regulatory setbacks, including an FDA rejection for Izervay to broaden its label.In February, Astellas received a much-needed boost when the FDA lifted a 12-month restriction on the use of Izervay. With that and the sales upturn, the company said on Wednesday that it expects to hold 55% to 60% of the market share in the U.S. by 2029.

10 Jul 2025

·endpoints.news

Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future

In a historic first, the FDA on Thursday released about 200 novel and generic drug rejection letters, bucking the agency’s former reticence to publicize the documents in one place. But it’s a small step as nearly all the letters reviewed by Endpoints News were previously disclosed as part of the drugs’ approval packages. Two of the complete response letters not previously disclosed included one for AstraZeneca’s COPD treatment Breztri Aerosphere in 2019 and one for a label update for Astellas’ eye drug Izervay in 2024. All of the rejection letters released are for drugs that have since been approved. AstraZeneca disclosed its CRL in a press release but did not mention that the FDA said the submitted data “do not provide substantial evidence of the efficacy and safety for the use of Breztri Aerosphere.” The CRL also said “the single Aerosphere phase 3 pivotal trial failed on the co-primary endpoint of change from baseline in trough FEV1 for the comparison of Breztri Aerosphere and the glycopyrrolate and formoterol fumarate combination.” AstraZeneca said in a statement to Endpoints that its 2019 press release on the Breztri complete response letter “is an accurate reflection of the status of the regulatory filing and data at the time.” Breztri was later approved in 2020 following submission of additional data. For Izervay’s label expansion, Astellas also announced the CRL in a press release in 2024, but said the FDA comments outlined in the CRL “focus on a statistical matter” and “are unrelated to the safety and benefit/risk of the use of IZERVAY.” The FDA, however, said in the CRL that the company’s proposal to extend the dosing interval “was not supported by the submitted data and was not replicated in a second adequate and well controlled study.” Astellas did not immediately respond to a request for comment. The FDA noted that according to a 2015 analysis conducted by FDA researchers, drug companies “avoided mentioning 85% of the FDA’s concerns about safety and efficacy when announcing publicly that their application was not approved. Moreover, when FDA calls for a new clinical trial for safety or efficacy, that critical information is not disclosed approximately 40% of the time.” The FDA said the CRLs have been redacted for trade secrets and confidential commercial information. It’s unclear if the agency contacted the sponsors prior to releasing the new letters. The agency also said it is in the process of publishing additional CRLs from its archives. “For far too long, drug developers have been playing a guessing game when navigating the FDA,” FDA Commissioner Marty Makary said in a statement. “Drug developers and capital markets alike want predictability. So today we’re one step closer to delivering it to them, with an ultimate goal of bringing cures and meaningful treatments to patients faster.” Editor’s Note: This story was updated with comment from AstraZeneca. An earlier version was updated to reflect a review of the documents released today, finding that some were previously disclosed in approval packages.

Phase 3Drug Approval

100 Deals associated with Avacincaptad pegol

External Link

KEGG	Wiki	ATC	Drug Bank
D11748	-	-	DB15165

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Geographic Atrophy	United States	Astellas Pharma US, Inc.	04 Aug 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Age Related Macular Degeneration	NDA/BLA	Canada	Astellas Pharma Canada, Inc.	01 Feb 2025
Blindness	Phase 3	Japan	Astellas Pharma, Inc.	08 Jul 2025
dry age-related macular degeneration	Phase 3	United States	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Argentina	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Australia	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Austria	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Belgium	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Brazil	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Canada	IVERIC bio, Inc.	22 Jun 2020
dry age-related macular degeneration	Phase 3	Colombia	IVERIC bio, Inc.	22 Jun 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02686658 \| NCT04435366 (GATHER2, EURETINA2024) Manual	Phase 2/3	Geographic Atrophy	-	Avacincaptad Pegol 2 mg	domznvkkhy(iucgkhhyqc) = uhlgejbxqw nnyxzmtsjz (jqebflthnt )	Positive	19 Sep 2024
NCT04435366 (GATHER2, PRNewswire) Manual	Phase 3	Age Related Macular Degeneration	-	IZERVAY	tdbtknztsi(cqbmbrtwlv) = IZERVAY was well tolerated over 2 years, with one case each of non-serious intraocular inflammation (IOI) and culture-positive endophthalmitis. There were no cases of ischemic neuropathy or retinal vasculitis. fzycthxzog (jtahghetmf ) View more	Positive	04 Nov 2023
				IZERVAY
EURETINA2023	Not Applicable	Geographic Atrophy	-	Avacincaptad pegol 2 mg	ebjsbtaikb(zhqnpmlqrl) = axtvefefcn lxgklikqtn (whqphxzeug, 0.56 - 0.15-2.06)	-	05 Oct 2023
EURETINA2023	Not Applicable	-	-	Avacincaptad pegol 2 mg	bujuhxrehe(kyfeqpkbcg) = ygsndekcph gjeqoprplj (erpxgmlang ) View more	-	05 Oct 2023
NCT02686658 \| NCT04435366 (GATHER2, FDA) Manual	Phase 2/3	Geographic Atrophy	624	IZERVAY (GATHER1)	pxqlyunwdz(hwdhrggfvj) = ipggbfclqb ophmviszsp (gvedqqglwv )	Positive	04 Aug 2023
				Sham (GATHER1)	pxqlyunwdz(hwdhrggfvj) = zvfekxskra ophmviszsp (gvedqqglwv )
NCT04435366 (GATHER2, Corporate Publications) Manual	Phase 3	Geographic Atrophy	447	Avacincaptad pegol	lzifimiuzz(tnhlzpchby) = bcbfilvcfi monsuhvrux (sygaezlqqa ) View more	Positive	06 Sep 2022
				Sham	lzifimiuzz(tnhlzpchby) = jxmpkssxec monsuhvrux (sygaezlqqa ) View more
NCT02686658 (GATHER1, ARVO2022)	Phase 2/3	Geographic Atrophy	-	Avacincaptad pegol 2 mg	kllvfzukkf(fqxnxdzzdd) = mkobduluvn meihrmlvzk (vrtqgjiweb )	-	01 May 2022
				avacincaptad pegol (Sham)	kllvfzukkf(fqxnxdzzdd) = ufmjxjejca meihrmlvzk (vrtqgjiweb )
NCT03362190 (CTgov)	Phase 2	Wet age-related macular degeneration	64	Avacincaptad Pegol+Lucentis (Cohort 1)	jtaixopiey = orotwobxuq dzvlxcmoui (yuhmdslmlr, waklqeadry - woavwsdpio) View more	-	02 Feb 2022
				Avacincaptad Pegol+Lucentis (Cohort 2)	jtaixopiey = rqudzyecsm dzvlxcmoui (yuhmdslmlr, poypajqpxb - ihajbbumuw) View more
NCT02686658 (GATHER1, AAO2021)	Phase 2/3	dry age-related macular degeneration \| Geographic Atrophy	286	Avacincaptad Pegol 2mg	kwjweghngf(pcjjydtlnc) = zviejdwfyz hwhxfkkfwm (bdowbmyoqt )	-	13 Nov 2021
				Avacincaptad Pegol 4mg	kwjweghngf(pcjjydtlnc) = kiptgxiwyo hwhxfkkfwm (bdowbmyoqt )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis